trending Market Intelligence /marketintelligence/en/news-insights/trending/kss1frq0c1r2j_h1okbafw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

ViiV Healthcare commences phase 3 study of HIV infection prevention drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


ViiV Healthcare commences phase 3 study of HIV infection prevention drug

ViiV Healthcare, majority-owned by GlaxoSmithKline PLC with Pfizer Inc. and Shionogi & Co. Ltd. as shareholders, started a phase 3 study of cabotegravir, its injectable treatment for the prevention of HIV.

The study will compare the injection given every two months against the daily oral pre-exposure prophylaxis with Gilead Sciences Inc.'s Truvada. It is being conducted through a public-private collaboration of ViiV Healthcare, the HIV Prevention Trials Network, the U.S. National Institute of Allergy and Infectious Disease and Gilead Sciences.

The first phase 3 study will enroll about 4,500 men and transgender women at more than 40 sites in North and South America, Asia and Africa. A second phase 3 study for the prevention of HIV infection in young women is expected to start in 2017.